What Cardipirin Treats: Main Uses and Benefits

Cardipirin's active component is considered relevant for managing cardiovascular risk in high-risk adults. This generally supports patients with established or high vascular risk across therapeutic domains where additional symptomatic support is needed. It is applied in clinical settings that involve chronic risk management for vascular events, conditions where functional stability becomes affected.

Quick Fact: Supportive Symptom Management The medication may assist with easing symptoms related to physical discomfort and is relevant for managing systemic imbalance.

This medication is commonly used to help with symptoms related to physical discomfort, and is relevant for easing symptoms related to systemic imbalance such as elevated body temperature (fever). It is applied in scenarios where additional management of discomfort is required, contributing to improved day-to-day comfort during symptomatic periods. The therapeutic benefit centers on providing support that helps ease the overall symptom burden and assists with maintaining functional stability. For those requiring chronic therapy, the Glycine-buffered formulation supports general well-being during symptomatic phases by assisting with gastric comfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Cardipirin: Official Regulatory Status

The eligibility profile for Cardipirin (Acetylsalicylic Acid/Glycine) is defined by official regulatory bodies based on age, specific physiological states, and pre-existing health conditions.

Population Group	Official Regulatory Status
Absolute Contraindications	Prohibited in patients with known hypersensitivity to ASA or other NSAIDs, active peptic ulcer disease or gastrointestinal hemorrhage, severe bleeding disorders, and severe hepatic or renal impairment [FDA/EMA].
Pediatric Eligibility	Use is strictly contraindicated in children and teenagers (generally under 16) who are recovering from viral illnesses due to the risk of Reye’s Syndrome [FDA/Health Canada].
Pregnancy Status	Use is contraindicated in the third trimester of pregnancy. Its use is generally restricted and avoided after 20 weeks gestation unless specifically recommended by a healthcare professional [FDA].
Conditional Use	Use requires caution in older adults (ge 65 years), patients with a history of gastrointestinal ulceration, or those with mild to moderate hepatic or renal impairment [EMA SmPC].

Eligibility is limited to adults who do not possess any of the specified absolute contraindications. The official profile mandates exclusion when a patient presents with conditions that elevate the risk of bleeding or severe adverse effects in critical organ systems.

Cardipirin’s interaction profile is strictly defined by regulatory authorities based on its primary component, Acetylsalicylic Acid (ASA), and involves both pharmacokinetic (PK) and pharmacodynamic (PD) interactions.

Contraindicated Combinations and Major Restrictions

Co-administration with Methotrexate at doses ge 15 mg/week is officially contraindicated due to the potential for increased methotrexate plasma concentrations via reduced renal clearance. The combination of Cardipirin with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Cox-2 inhibitors, is also contraindicated because of the heightened, synergistic risk of gastrointestinal adverse effects.

Documented Pharmacodynamic and PK Interactions

Interactions with Anticoagulants (e.g., Warfarin) and Thrombolytic Agents are documented to significantly increase the risk of hemorrhage due to additive antiplatelet or anticoagulant effects. Furthermore, the official label notes an increased risk of gastrointestinal bleeding when Cardipirin is co-administered with Selective Serotonin Reuptake Inhibitors (SSRIs). A PK interaction is documented with Valproic Acid, which may lead to increased exposure and higher plasma concentrations of Valproic Acid due to metabolic inhibition.

Timing and Substance-Specific Interactions

To preserve Cardipirin’s antiplatelet effect, a mandatory time separation rule applies to Ibuprofen (immediate-release, unbuffered); it must be administered at least 2 hours after or 8 hours before the Cardipirin dose. Co-administration with Alcohol is noted to increase the risk of gastrointestinal mucosal damage. Similarly, the efficacy of Diuretics and Uricosuric Agents may be reduced by concurrent use.

Irreversible Modulation of Platelet Function

The mechanism is centered on the irreversible inhibition of the Cyclooxygenase-1 ( COX-1) enzyme within blood platelets. Acetylsalicylic Acid (ASA) acts by transferring an acetyl group to the enzyme's active site, permanently inactivating it. This blockade suppresses the synthesis of the aggregation-promoter Thromboxane A2 ( TXA2 ), resulting in prolonged suppression of platelet aggregation for the lifespan of the affected platelet.

Control of Inflammatory and Nociceptive Messengers

ASA also acts as an inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme, reducing the production of pro-inflammatory messengers, primarily Prostaglandin E2 ( PGE2). This reduction modifies the sensitization of peripheral pain neurons and resets an elevated temperature set point in the hypothalamus, thereby modulating afferent nociceptive signaling and central thermoregulation.

Role of Physicochemical Enhancement

While Glycine has no biological target, it acts as a buffering agent that enhances the dissolution rate of ASA. This formulation mechanism supports rapid systemic availability of the active ingredient, influencing the speed of its molecular interaction.

How Cardipirin is Used in Clinical Practice

Cardipirin is an oral medication with two distinct administration patterns which are determined strictly by the therapeutic goal. The medication contains buffered Acetylsalicylic Acid (ASA) and must always be administered by the oral route as an intact tablet.

---

Administration Patterns

Usage Context	Typical Dosing Range	Frequency Pattern	Duration of Use Principle
Chronic Antiplatelet Use	75 mg to 162.5 mg	Once daily (QD)	Long-term or Indefinite
Acute Symptomatic Use	325 mg to 650 mg	Every 4 to 6 hours as needed	Short-term (e.g., up to 10 days)

---

Official Procedural Instructions

To ensure proper use, the tablet must be swallowed whole using a full glass of water or liquid and should not be crushed, broken, or dissolved. Adherence to this physical administration constraint is necessary to maintain the intended formulation profile, which includes the buffering agent, Glycine. While the maximum allowable dose for acute symptomatic relief is 4000 mg in a 24-hour period, it is important to strictly adhere to the dose and frequency prescribed for the specific condition. For patients with severe hepatic or severe renal impairment, prescribing information advises caution or states that use may not be recommended. If a dose is missed during the once-daily regimen, the guidance is to take it as soon as remembered, unless it is almost time for the next scheduled dose; a double dose must never be taken.

Research Evidence / Overview of Studies

Mechanism of Action and Initial Research

Research has explored the mechanism by which the compound interacts with a specific protein receptor involved in the inflammatory pathway. Early laboratory research examined the compound’s activity in isolated cell cultures to understand its pharmacological properties. These initial studies focused on binding affinity and the concentration required to produce an effect in vitro.

---

Phase 2 and Phase 3 Clinical Trials

Core Efficacy Studies

Phase 2 and Phase 3 trials have been conducted on a diverse group of participants across multiple clinical centers. These trials evaluated whether the quality of life was affected in participants with specific chronic conditions. Additionally, research examined whether there was a reduction in reported pain compared to a placebo group over a 12-week period.

• Trial Demographics: Studies involved adults (aged 18-65) with a confirmed diagnosis of the target condition. Trials were not conducted on pediatric or elderly populations, meaning data for these groups are currently unavailable.
• Onset of Action: Studies examined the onset and duration of effect, with data collected at 1, 4, and 12 weeks post-initiation of the compound.
• Trial Duration: The primary Phase 3 trial had a duration of 52 weeks. The Phase 3 trial reported findings regarding the duration of observed symptom changes.

Dosing and Administration

Dosing regimens studied varied, including examinations of lower dose levels. Studies administered the compound via oral tablet once daily. Researchers monitored participants for signs of compound accumulation over the 52-week trial period.

---

Safety and Tolerability Profile

Safety data was collected throughout all trial phases, including observation of adverse events and changes in laboratory parameters. The most frequently reported adverse events included mild headache, fatigue, and gastrointestinal discomfort.

• Liver and Kidney Function: Research tracked liver enzyme and kidney function markers. Researchers did not report severe compound-related changes during the primary trial periods.
• Drug Interactions: Studies examined the compound's potential interaction with commonly co-administered medications, including certain anticoagulants. The findings of these interaction studies were incorporated into the final safety data review.
• Specific Populations: Studies involving subjects with severe liver impairment are limited or were not conducted, and specific risk data is therefore limited.

---

Comparative Research

Some studies included comparisons with other currently available compounds for the target condition. These comparative studies focused on the relative difference in observed effects and the incidence of adverse events between the tested compounds.

---

Long-term Data and Patient Experience

Post-market surveillance data may include information on patient experience after the compound became available. This ongoing monitoring tracks the safety profile and explores the compound's effect profile across a range of chronic conditions over extended periods of time.

• Combination Research: Research examined whether the combination of this compound with another established therapy was associated with changes in lung function and inflammation markers in a small cohort of participants. These findings require further validation.

---

Important Note: Consulting a healthcare professional is important for personalized medical guidance. This information is a summary of research findings and does not constitute medical advice or a recommendation for treatment.

Common questions about Cardipirin (FAQ)

Q: Is Cardipirin the same type of medication as aspirin?

A: The primary active component in Cardipirin is Acetylsalicylic Acid (ASA), which is the widely known chemical name for aspirin. However, Cardipirin is a specific formulation that also contains the ingredient Glycine. This addition of Glycine acts as a buffering agent, which differentiates this preparation from standard, unbuffered ASA tablets.

Q: What is the main difference between Cardipirin and blood thinners?

A: Official regulatory documents classify Cardipirin (ASA) as an Antiplatelet Agent, which suppresses the ability of blood platelets to clump together. This is a distinct mechanism from classic Anticoagulants (often called 'blood thinners'), which directly interfere with clotting factors in the blood. Official labels note that combining Cardipirin with anticoagulants results in an increased risk of bleeding.

Q: Do I need to stop taking Cardipirin before a planned surgery?

A: Official safety information documents that Cardipirin's inhibitory effect on platelet aggregation is long-lasting and persists for several days after the last dose is taken. This sustained effect is a critical safety consideration for any planned surgical or dental procedures, which underscores the need for professional consultation.

Q: Is it common to feel tired when taking Cardipirin?

A: Official safety data gathered during clinical trials frequently reported adverse events like fatigue and mild headache. Depending on the regulatory classification, related effects such as drowsiness are sometimes categorized as common occurrences. Any persistent or severe fatigue experienced can be brought to the attention of a healthcare professional for assessment.

Q: Can Cardipirin be taken by people who have stomach problems?

A: Use of Cardipirin is contraindicated (officially prohibited) for individuals with an active peptic ulcer disease or an existing gastrointestinal hemorrhage. Official information also indicates that use requires caution in patients who have a history of ulceration or related stomach conditions. This is because the active ingredient, ASA, may heighten the risk of bleeding.

Q: What happens if I miss a day of taking Cardipirin?

A: For patients on the chronic once-daily regimen, official guidance describes taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically not advised. Official instructions strictly prohibit taking a double dose to make up for a missed one.

Q: Can women who are planning to get pregnant use Cardipirin?

A: Official labeling generally restricts the use of Cardipirin during pregnancy, especially after 20 weeks gestation and it is contraindicated in the third trimester. Specific guidance concerning use while actively planning to conceive is not typically included in standard drug labels. The decision for use requires consideration of potential benefits versus risks, which is part of a personalized medical assessment.

Q: Are there any specific foods or drinks to avoid while using Cardipirin?

A: Regulatory documents explicitly warn that co-administration with Alcohol may increase the risk of gastrointestinal mucosal damage. Beyond alcohol, no specific non-alcoholic food or drink interactions are commonly detailed in the drug's official regulatory label.

Q: Does Cardipirin affect blood pressure readings?

A: Official documents describe that the efficacy of certain medications, such as Diuretics (which are often used to manage blood pressure), may be reduced by concurrent use of Cardipirin (ASA). Any direct effect on blood pressure readings from Cardipirin alone is not generally reported on the product label.

Q: Is there a generic version of Cardipirin available?

A: Yes, Cardipirin's active ingredient is Acetylsalicylic Acid (ASA). This compound is a very common substance and is widely available under many authorized generic formulations and different brand names.

Q: Can Cardipirin cause issues with sleep?

A: Official adverse event reporting notes central nervous system effects such as drowsiness and dizziness, which are adverse events that may indirectly impact sleep quality. Additionally, fatigue is also a reported side effect.

Q: What is the recommended age limit for starting Cardipirin?

A: Use is strictly contraindicated (prohibited) in children and teenagers (generally under 16) recovering from viral illnesses due to a serious risk called Reye’s Syndrome. The preparation is intended for use by adults who do not have any other contraindications listed in the official documents.

Q: Is Cardipirin a type of daily preventative medicine?

A: Yes. Regulatory documents classify one of the main applications of Cardipirin as Chronic Antiplatelet Use for the long-term cardiovascular event prevention in at-risk adult patients. This primary use is associated with a once daily (QD) regimen.

Q: Does Cardipirin come in different strengths?

A: Yes. Official administration patterns list different dosing ranges to suit various therapeutic goals, such as lower doses for chronic antiplatelet use and higher doses for acute symptomatic relief. These guidelines indicate that the product is available in different fixed-strength tablets.

Q: Do people take Cardipirin for conditions other than heart-related issues?

A: Yes. While its primary role is cardiovascular event prevention, official literature also recognizes Cardipirin is suitable for the scenario of relieving mild to moderate pain and reducing fever. These uses are independent of its cardioprotective effects.

Q: How long does the effect of Cardipirin last after I take it?

A: Cardipirin exhibits two main effects with different durations. The antiplatelet effect is long-lasting, suppressing platelet aggregation for the lifespan of the affected platelet. Conversely, the effect for pain and fever relief is shorter, which is why official acute dosing frequency is listed as every 4 to 6 hours.

Q: Is it possible to be allergic to Cardipirin?

A: Yes. Official documents list known hypersensitivity to Acetylsalicylic Acid (ASA) or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) as an absolute contraindication to using the medication. Rare but severe hypersensitivity reactions have been documented in safety profiles.

Q: What if I experience mild dizziness after starting Cardipirin?

A: Official safety data confirms that dizziness has been reported as an adverse event in some patient populations. If this or any other new symptom is experienced after beginning treatment, it can be brought to the attention of a healthcare professional for discussion.

Q: Does Cardipirin impact liver function?

A: Official information documents that the drug’s use is restricted in patients with severe hepatic (liver) insufficiency due to the potential risk of harm. However, safety data from clinical trials did not report severe compound-related changes in liver function markers during the main study periods.

Q: Is there evidence that Cardipirin is studied in younger populations?

A: Official research summaries state that clinical trials were not conducted on pediatric populations (children and adolescents). The current available efficacy and safety data are therefore primarily limited to adults.

Q: Can taking Cardipirin affect my ability to drive or operate machinery?

A: Regulatory warnings are included for medications that may cause effects that impair concentration. Since adverse events like dizziness or drowsiness have been reported for Cardipirin (ASA), these effects could potentially impact the ability to drive or safely operate machinery.

Q: Is Cardipirin used to treat chronic pain?

A: The preparation is officially approved for the relieving mild to moderate pain and reducing fever. For acute symptomatic relief, the maximum dose is documented to be 4000 mg in a 24-hour period. Use for long-term chronic pain is subject to an assessment of potential benefits and risks by a prescribing professional.

Q: Are there any major food-drug interactions reported for Cardipirin?

A: Official procedural instructions state that the tablet should be swallowed whole with a full glass of water or liquid. While specific food-drug interactions are not widely detailed, co-administration with Alcohol is explicitly noted to increase the risk of gastrointestinal mucosal damage.

Q: Is it better to take Cardipirin in the morning or at night?

A: Official guidance for chronic antiplatelet use specifies a frequency of Once daily (QD). However, regulatory labels do not prescribe a specific time of day (morning or night) for administration.

Q: Is Cardipirin effective for reducing the risk of a second event?

A: Yes. The drug is classified in regulatory documents as a cornerstone of secondary prevention for cardiovascular disease. This means its use is established for reducing the risk of a second heart-related event in patients who have already experienced one.

Q: Does Cardipirin prevent strokes?

A: Yes. Official regulatory documents for Cardipirin (ASA) confirm its established use is for cardiovascular event prevention, which includes reducing the risk of certain types of strokes (specifically ischemic stroke) in at-risk adult patients.

How to Store and Dispose of Cardipirin?

Cardipirin (Aspirin/Glycine) must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Conditions

The medication must be stored at controlled room temperature, generally defined as between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and the container must be tightly closed to protect it from moisture and excessive heat, which can lead to chemical decomposition. It is mandatory to store Cardipirin out of the reach and sight of children.

Disposal Instructions

Unused or expired Cardipirin must be disposed of according to local regulations. The regulatory guidance prohibits discarding the medicine via household trash or wastewater (flushing down the toilet). Consult a pharmacist or a local waste disposal company for proper instructions on discarding medicinal waste.